Purchase Order 75N92025P00345
Award Date
8/28/25
Potential Completion Date
11/1/25
Potential Value
$22K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Proteogenix
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
France
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
<p>The Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute awarded a Firm Fixed Price Purchase Order to Proteogenix, a for-profit manufacturer, to provide phage-display library screening services to develop in vivo gene therapy. The contract has a potential value of $46,260.00 and a completion date of April 21, 2025. The contract was awarded on April 22, 2024 and does not have a set-aside designation.</p>
The National Heart Lung and Blood Institute (NHLBI), a civilian agency within the U.S. government, awarded a $229,104 firm fixed-price purchase order contract to Psomagen Inc., a for-profit organization and manufacturer of goods. The contract, which has no set-aside designation, is for investigating transthyretin (TTR) variants and their impact on sickle cell disease severity using Olink proteomics technology. This contract is part of a larger $500 million single-award Indefinite Delivery...
The National Heart, Lung and Blood Institute of the National Institutes of Health, Department of Health and Human Services, awarded a $224,000 purchase order to Cell Signaling Technology, Inc. of Danvers, Massachusetts for proteome analysis services. The one-year contract, running from August 2024 through August 2025, is for a firm fixed price and will be performed in Danvers. As part of its mission to advance scientific and medical achievements that eliminate preventable disease, the NHLBI...
The National Heart Lung and Blood Institute (NHLBI), a civilian agency within the National Institutes of Health (NIH), awarded a $34,966 firm fixed-price purchase order to Mission Bio, Inc., a for-profit manufacturer of biological supplies and sequencing services. The contract is for the delivery of Tapestri Single-Cell DNA + Protein Reagent Kits to support NHLBI's biomedical research and genomics efforts. The contract has a performance period through December 19, 2025 and does not utilize any...
The National Heart Lung and Blood Institute (NHLBI) awarded a $81,200.00 firm fixed price purchase order contract to Second Genome, Inc. for MICROBIOME OPTIMIZED DNA ISOLATION SERVICES. The contract has a completion date of August 27, 2018 and is designated as a Total Small Business set-aside. Second Genome, Inc. is a self-certified small disadvantaged business. The NHLBI is a civilian agency that conducts and supports research related to the causes, prevention, diagnosis, and treatment of...
This federal contract award was issued by the National Heart Lung and Blood Institute (NHLBI), a civilian agency, to Bruker Spatial Biology, Inc., a for-profit manufacturer of advanced scientific instrumentation and related services. The $24,281 firm fixed-price contract is for the provision of transcriptomics panels to support patient sample experiments at the NHLBI lab. The contract is not designated as a set-aside. The award is associated with a $10,000,000 Blanket Purchase Agreement (BPA)...
<p>This is a $29,700.00 Firm Fixed Price purchase order contract awarded by the National Heart Lung and Blood Institute, a civilian agency, to Proteogenix, a for-profit manufacturer, for a phage-display VHH antibody screening service to develop in vivo gene therapy. The contract has an ultimate completion date of August 6, 2025. The contract was awarded on August 7, 2024 and does not have a set-aside designation.</p>
The National Heart, Lung and Blood Institute (NHLBI) has awarded a $14,097.60 firm fixed price purchase order to Psomagen Inc., a for-profit organization and manufacturer of goods, to provide transcriptome profiling of human bone marrow core samples. The work supports the Hematology Branch at NHLBI. This is not a set-aside contract. Psomagen Inc. is a subsidiary of Macrogen, Inc. and operates CLIA-certified and CAP-accredited facilities. The company has a $500 million single-award Indefinite...
The National Heart, Lung, and Blood Institute (NHLBI), a civilian agency within the U.S. Department of Health and Human Services, awarded a firm fixed-price contract valued at $18,120.00 to Stemcell Technologies Inc., a foreign-owned, for-profit biotechnology company based in Canada. The contract is a Blanket Purchase Agreement (BPA) call, with an ultimate completion date of May 18, 2025. The purpose of the contract is to provide cell purification kits to the NHLBI LEONARD LAB in order to purify...
<p>The National Heart Lung and Blood Institute (NHLBI), a civilian agency, has awarded a $120,000.00 firm fixed price purchase order contract to Bionik LLC for vector production and purification services. The contract has an ultimate completion date of October 31, 2024 and was awarded on September 1, 2023. This contract is not associated with any set-aside designation.</p>